Search

Aims: To compare the smear layer removal efficacy of 17% ethylenediaminetetraacetic acid (EDTA), 0.2% Chitosan nanoparticles, and QMIX 2 in 1 at apical third of root canal system, using Endovac system (Kerr, Switzerland) irrigation system and analyzed with the scanning electron microscope (SEM). Materials and Methods: Forty-five extracted mandibular single-rooted premolar noncarious human teeth were selected. The samples were randomly divided into three groups: Group 1: Irrigated with 1 ml of 17% EDTA, Group 2: With 0.2% Chitosan nanoparticles, and Group 3: With QMix2in1 (Dentsply Sirona, USA); 15 teeth in each group as final irrigant. The root canals were sequentially cleaned and shaped till 0.30 mm/0.09 taper and were irrigated with 1 ml of 5% sodium hypochlorite and 1 ml of 0.9% saline, after introducing each file into the canal. Endovac system (Kerr, Switzerland) system was used as delivering unit for all irrigation solutions with separate syringes. The tooth samples were sectioned and analyzed under SEM. The data obtained were analyzed using the Chi–square test. Results: All three irrigation solution in Group 1, Group 2, and Group 3 removed smear layer. Group 3 showed a significant difference in smear layer removal from the root canal system than Group 1 and Group 2. Conclusions: The final irrigation with QMix2in1 (Dentsply Sirona, USA) solution aids in better smear layer removal at the apical third of the root canal system, using Endovac system (Kerr, Switzerland) irrigation system.

Meloxicam (MLX) is currently used in the therapeutic management of both acute and chronic inflammatory disorders such as pain, injuries, osteoarthritis, and rheumatoid arthritis in both humans and animals. Gastrointestinal toxicity and occasional renal toxicity were observed in patients taking it for a long-term period. Meloxicam’s late attainment of peak plasma concentration results in a slow onset of action. The goal of the current study was to prepare and characterize chitosan encapsulated meloxicam nanoparticles (CEMNPs) with high bioavailability and less gastro intestinal toxicity in order to prevent such issues. The size of the prepared CEMNPs was approximately 110–220 nm with a zetapotential of +39.9 mV and polydispersity index of 0.268, suggesting that they were uniformly dispersed nanoparticles. The FTIR and UV-Vis spectroscopy have confirmed the presence of MLX in the prepared CEMNPs. The pharmacokinetics have been studied with three groups of male Wistar rats receiving either of the treatments, viz., 4 mg·kg−1 of MLX and 1 or 4 mg·kg−1 of CEMNPs. Plasma samples were collected until 48 h post administration, and concentrations of MLX were quantified by using reverse (C18) phase HPLC. Non-compartmental analysis was applied to determine pharmacokinetic variables. Upon oral administration, the maximum concentration (Cmax) was reached in 4 h for CEMNPs and 6 h for MLX. The mean area under the plasma MLX concentration-time curve from ‘zero’ to infinity (AUC0–∞), half-life (t1/2β), and mean resident time (MRT) of 1 mg·kg−1 of CEMNPs was 1.4-, 2-, and 1.8-fold greater than 4 mg·kg−1 of MLX. The prepared CEMNPs demonstrated quicker absorption and prolonged release along with a significant improvement in the bioavailability of MLX, paving a prospective path for the development of drugs with enhanced bioavailability with less side effects.

Meloxicam (MLX) is currently used in the therapeutic management of both acute and chronic inflammatory disorders such as pain, injuries, osteoarthritis, and rheumatoid arthritis in both humans and animals. Gastrointestinal toxicity and occasional renal toxicity were observed in patients taking it for a long-term period. Meloxicam's late attainment of peak plasma concentration results in a slow onset of action. The goal of the current study was to prepare and characterize chitosan encapsulated meloxicam nanoparticles (CEMNPs) with high bioavailability and less gastro intestinal toxicity in order to prevent such issues. The size of the prepared CEMNPs was approximately 110–220 nm with a zetapotential of +39.9 mV and polydispersity index of 0.268, suggesting that they were uniformly dispersed nanoparticles. The FTIR and UV-Vis spectroscopy have confirmed the presence of MLX in the prepared CEMNPs. The pharmacokinetics have been studied with three groups of male Wistar rats receiving either of the treatments, viz., 4 mg·kg−1 of MLX and 1 or 4 mg·kg−1 of CEMNPs. Plasma samples were collected until 48 h post administration, and concentrations of MLX were quantified by using reverse (C18) phase HPLC. Non-compartmental analysis was applied to determine pharmacokinetic variables. Upon oral administration, the maximum concentration (Cmax) was reached in 4 h for CEMNPs and 6 h for MLX. The mean area under the plasma MLX concentration-time curve from 'zero' to infinity (AUC0–∞), half-life (t1/2β), and mean resident time (MRT) of 1 mg·kg−1 of CEMNPs was 1.4-, 2-, and 1.8-fold greater than 4 mg·kg−1 of MLX. The prepared CEMNPs demonstrated quicker absorption and prolonged release along with a significant improvement in the bioavailability of MLX, paving a prospective path for the development of drugs with enhanced bioavailability with less side effects. [ABSTRACT FROM AUTHOR]

Chitosan nanoparticles (CSNPs) have been recently used for various applications in aquaculture, especially as drug carriers. The aim of this study was to synthesise and investigate a superlative method of CSNP synthesis for application in aquaculture through aquaculture‐based toxicology screening methods. Two different methods were analysed: the first a direct ionic gelation method (A) and the other involving a low‐molecular‐weight chitosan microparticle intermediate method (B). Dynamic light scattering characterisation revealed that the CSNP particle sizes were 192.7 ± 11.8 and 22.9 nm from methods A and B, respectively. The LC50 values for brine shrimp toxicity were found to be 1.51 and 0.02 ppt in 24 h for methods A and B, respectively. Acute toxicity studies in Litopenaeus vannamei rendered LC50 values of 3235.94 and 2884.03 ppt in 24 h for methods A and B, respectively. Zebrafish toxicity studies revealed mortality rates of 21.67% and 55% at 20 mg/L concentration for methods A and B, respectively, with an increased expression of intracellular reactive oxygen species in method B. From these findings, it can be concluded that a comparatively reduced toxicity of CSNPs derived from ionic gelation method makes it more appropriate for application in aquaculture. [ABSTRACT FROM AUTHOR]

Abstract:The present research looked for ways to develop shielded nanoparticles (NPs)-drug transporters made of chitosan (CS) to enhance the bioavailability of Edoxaban tosylate monohydrate (ETM) for oral administration by examining the correlation among design aspects and data from experiments using response surface methodology. ETM-loaded CS nanoparticles (ETM-CS-NPs) were developed using the ionic gelation of CS with tripolyphosphate (TPP). Utilizing Zeta-sizer and scanning electron microscopy, the ETM-CS-NPs were evaluated for particle size (PS), zeta potential (ZP), surface morphology, polydispersity index (PDI), entrapment efficiency (EE), and drug loading (DL). Drug and polymer interactions in NPs were assessed using Fourier transform infrared spectroscopy. The response surface approach and Design-Expert software optimized the ETM-CS-NPs. Using response surface methodology, the effects of independent variables such as the amount of CS, the amount of TPP, and the amount of glacial acetic acid on PS, PDI, and ZP were analyzed. The optimal combination of PS (354.8 nm), PDI (0.509), ZP (43.7 + mV), % EE (70.3 ± 1.3), and % DL (9.1 ± 0.4) has been identified for the optimized ETM-CS-NPs. ETM-CS-NPs' anticoagulant activity was evaluated using activated partial thromboplastin time (aPTT), prothrombin time (PT), and thrombin time (TT) assays. In conclusion, a practical and consistent method has been established, and its application has been proven in vitro, indicating its utility for future studies of the biological distribution of ETM-CS-NPs in vivo for specific antithrombotic treatments. [ABSTRACT FROM AUTHOR]